Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7601-7610 Newer>

The Motley Fool July 1, 2011 Brian Orelli	Dendreon Is Drama-Free ... for Now For a drug that has had so much drama during its existence, the final decision by the Centers for Medicare and Medicaid Services to pay for Dendreon's prostate cancer treatment Provenge was pretty anticlimactic.
The Motley Fool July 1, 2011 Brian Orelli	What Will Cell Therapeutics Do With Your Money? Unfortunately the answer is probably, "buying a drug."
The Motley Fool July 1, 2011 David Williamson	Dentsply Acquisition Delivers Smiles This smart deal makes money right off the bat.
The Motley Fool July 1, 2011 Luke Timmerman	Dendreon Sways Medicare to Pay for Prostate Cancer Drug The decision by Medicare is no surprise, but it does conclude a period of uncertainty about insurance reimbursement for its lone marketed product.
The Motley Fool July 1, 2011 Alex Crawford	3 Biotech Drugs With Promising Phase III Data, Moving Into FDA Review Do these drugs have a chance of FDA approval?
The Motley Fool June 30, 2011 David Williamson	Biotech Takes On the Next Big Problem The news coming out of this week's annual conference of the American Diabetes Association wasn't good.
The Motley Fool June 30, 2011 David Williamson	Pharmacy Benefits Delivering Drama CVS claims another Medco client and one messy split.
The Motley Fool June 30, 2011 Brian Orelli	Medical-Device Makers' Killer: Health-Care Inflation High prices have painted their targets.
The Motley Fool June 30, 2011 Brian Orelli	Biotech Winners of a Repatriation Holiday Biotechs and dividend players will come out ahead.
The Motley Fool June 30, 2011 Brian Orelli	Dendreon Increases Potential Output, More to Come Los Angeles plant is approved.
<Older 7601-7610 Newer> Return to current articles.